Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Every additional month of researcher use adds data points, but informal use doesn't replace structured clinical investigation
doi: 10.1021/jf981149l 20 ShenQShangNLiP
& Kumar, A
Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States
These data provide the rationale for extensive performance of surgical and percutaneous revascularization procedures in patients with CAD: over 600,000 such procedures are performed yearly in the United States across a population of 20 million patients with established disease
US$ 29.41
US$ 23.35
US$ 28.85
US$ 20.54
US$ 29.92
US$ 29.13
US$ 22.79
